Home/Filings/4/0001213900-18-013186
4//SEC Filing

Essetifin SPA 4

Accession 0001213900-18-013186

CIK 0000707511other

Filed

Sep 27, 8:00 PM ET

Accepted

Sep 28, 4:04 PM ET

Size

30.5 KB

Accession

0001213900-18-013186

Insider Transaction Report

Form 4
Period: 2018-09-27
Transactions
  • Conversion

    Common Stock

    2018-09-27$0.06/sh+3,133,681$188,02134,989,080 total
  • Conversion

    Convertible Promissory Note (right to buy)

    2018-09-27$150000.00/sh0 total
    Exercise: $0.06From: 2013-09-12Common Stock (3,133,681 underlying)
Transactions
  • Conversion

    Common Stock

    2018-09-27$0.06/sh+3,133,681$188,02134,989,080 total
  • Conversion

    Convertible Promissory Note (right to buy)

    2018-09-27$150000.00/sh0 total
    Exercise: $0.06From: 2013-09-12Common Stock (3,133,681 underlying)
Transactions
  • Conversion

    Common Stock

    2018-09-27$0.06/sh+3,133,681$188,02134,989,080 total
  • Conversion

    Convertible Promissory Note (right to buy)

    2018-09-27$150000.00/sh0 total
    Exercise: $0.06From: 2013-09-12Common Stock (3,133,681 underlying)
CAVAZZA PAOLO
10% Owner
Transactions
  • Conversion

    Common Stock

    2018-09-27$0.06/sh+3,133,681$188,02134,989,080 total
  • Conversion

    Convertible Promissory Note (right to buy)

    2018-09-27$150000.00/sh0 total
    Exercise: $0.06From: 2013-09-12Common Stock (3,133,681 underlying)
Transactions
  • Conversion

    Convertible Promissory Note (right to buy)

    2018-09-27$150000.00/sh0 total
    Exercise: $0.06From: 2013-09-12Common Stock (3,133,681 underlying)
  • Conversion

    Common Stock

    2018-09-27$0.06/sh+3,133,681$188,02134,989,080 total
Transactions
  • Conversion

    Common Stock

    2018-09-27$0.06/sh+3,133,681$188,02134,989,080 total
  • Conversion

    Convertible Promissory Note (right to buy)

    2018-09-27$150000.00/sh0 total
    Exercise: $0.06From: 2013-09-12Common Stock (3,133,681 underlying)
Footnotes (2)
  • [F1]On September 27, 2018, Essetifin S.p.A., an Italian corporation ("Essetifin"), exercised its option to convert the Convertible Promissory Note, originally issued on September 11, 2013 and reissued on March 13, 2018, in an initial principal amount of $150,000 (the "Note"), including all accrued but unpaid interest thereon, into shares of common stock, $0.001 par value per share (the "Common Stock"), of RegeneRx Biopharmaceuticals, Inc. (the "Company"). The Company issued a total of 3,133,681 shares of Common Stock to Essetifin upon conversion of the Note, including 633,681 shares of Common Stock issued in respect of the accrued but unpaid interest on the Note. As a result of the conversion and as of September 27, 2018, Essetifin directly owns 34,989,080 shares of Common Stock, which includes 3,133,681 shares of Common Stock that were issued upon conversion the Note.
  • [F2]Dispositive power over the shares of Common Stock owned by Essetifin is shared by Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza disclaims beneficial ownership of all shares of Common Stock held by Essetifin except to the extent of any pecuniary interest therein.

Issuer

REGENERX BIOPHARMACEUTICALS INC

CIK 0000707511

Entity typeother

Related Parties

1
  • filerCIK 0001092601

Filing Metadata

Form type
4
Filed
Sep 27, 8:00 PM ET
Accepted
Sep 28, 4:04 PM ET
Size
30.5 KB